Prognosis of chronic spontaneous urticaria with an inadequate response to omalizumab.

ABSTRACT:

Background

Chronic spontaneous urticaria (CSU) exhibits notable responsiveness to omalizumab (OMA). The prognosis and subsequent therapeutic strategies warrant comprehensive exploration in cases exhibiting inadequate responses to OMA.

Methods

We conducted a multicenter retrospective analysis to investigate the 12-month prognosis of patients inadequately responding to three injections of OMA. The endpoints encompassed identifying predictive factors for a favorable prognosis and assessing interventions related to an ameliorated prognostic outlook.

Results

The study involved 48 patients who met the inclusion criteria. After three OMA administrations, therapeutic interventions included the continuation of OMA in 34 patients, systemic corticosteroids in seven patients, and

SUBMITTER: Watanabe H 

PROVIDER: S-EPMC11771539 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature